Asthma

Atrial Fibrillation

Autoimmune Diseases

Biosimilars

Blood Cancer

COVID-19

Cardiovascular Diseases

Dermatology

Diabetes

Digital Health

Eyecare

Heart Failure

Hemophilia

Hypertrophic Cardiomyopathy (HCM)

Leukemia and Lymphoma

Liver Disease

Lung Cancer

Mental Health

Multiple Sclerosis

NSCLC

Neonatal Care

Obstetrics-Gynecology & Women's Health

Oncology

Opioids

Pediatrics

Plaque Psoriasis

Secondary Progressive Multiple Sclerosis: Patient Impact and Coverage Implications for New Therapies

Population Health

Post-Acute Care

Prescription Digital Therapeutics

Reproductive Health

Respiratory Conditions

Sleep Disorders

Solid Tumors

Spinal Muscular Atrophy

Substance Use Disorder

The Improving Patient Access Podcast

Type II Inflammation

Ulcerative Colitis

Urology

Urothelial Carcinoma

Vaccines

News

Media

Between the Lines

Expert Interviews

K-Cast

Medical World News

Podcasts

Population Health Perspectives

Conferences

Partners

Publications

All Publications

MHE Publication

Formulary Watch Supplements

Supplements And Featured Publications

Events

2023 PBMI Annual National Conference

Virtual Events

CME/CE

Resources

PBM Leaders

Subscribe

Print Subscription

eNewsletter

Articles


ICER has weighed in on two of the 10 drugs selected for negotiations: Eliquis and Xarelto, which are among Medicare Part D’s highest spending drugs.


CMS Moves Forward with Medicare Drug Price Negotiations


In a confirmatory trial, Exkivity did not meet the primary endpoint in treating patients with non-small cell lung cancer with EGFR exon 20 mutations. It will remain available while Takeda works with the FDA on withdrawal timing.


Takeda to Withdraw Oncology Drug Exkivity from U.S. Market

Director of Nonprofit Strategy, Patient Advocacy, IQVIA

Patient organizations should focus on how they can be the most effective by leveraging their strengths to uncover new research opportunities.

Maximizing Impact Through Strategic Research Investments That Address Unmet Needs


The FDA has approved several new therapies this week, including a new two-component Pompe therapy, an extended-release drug for major depression without sexual side effects, and an eye drop for drug-induced dilation. Additionally, the agency has set review dates for several products, including odronextamab for blood cancers, sotatercept for pulmonary arterial hypertension, and Dupixent in young children with eosinophilic esophagitis.


FDA Updates for the Week of Sept. 25, 2023

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Informations

Managed Healthcare Executive

Facebook

Twitter

LinkedIn

Resource Centers

Covid-19

Eye Care

Spotlight

AMCP Annual

ASRS

Asembia’s Specialty Pharmacy Summit

Business

Business Strategy

Chronic Disease

Consumers

Drug Costs

Drug Pipeline

Formulary

Health Management

Health/Disease Strategy

Hospitals & Providers

Industry Analysis

Pharmacy

Politics and Policy

Practice Management

Reimbursement

Technology

1rem

Authors

Health execs need to examine their current parental leave policies, for both men and women. Six-week-minimum maternity leave, breastfeeding support programs, and making moms aware of those policies can yield huge dividends.

Opinion: The Impact of Family-Forward Policies on Healthcare 

Marshall Staton

Articles